Trial Profile
Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanced Cervical Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2022
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cisplatin
- Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer; Uterine cancer
- Focus Therapeutic Use
- Acronyms ATEZOLACC
- 15 Feb 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2024.
- 15 Feb 2022 Planned primary completion date changed from 1 Jul 2021 to 1 Jul 2024.
- 23 Feb 2021 Planned primary completion date changed from 1 Jul 2020 to 1 Jul 2021.